Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial

Warner Postma, Enrico Fabris, Martin van der Ent, Rik Hermanides, Pawel Buszman, Clemens von Birgelen, Stéphane Cook, Hans Wedel, Giuseppe De Luca, Ronak Delewi, Felix Zijlstra, Elvin Kedhi

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objectives: To evaluate the safety and efficacy outcomes after primary percutaneous coronary intervention (pPCI) with second-generation Resolute™ zotarolimus-eluting stent (R-ZES) in patients enrolled in the DAPT-STEMI Trial (NCT01459627).

Background: R-ZES is one of the most used drug eluting stents worldwide. To date, the safety and efficacy data of this stent in setting of STEMI is limited.

Methods: The Resolute-STEMI is a prespecified prospective register that reports the safety and efficacy of R-ZES in setting of ST-Elevation Myocardial Infarction (STEMI) at 6 months for the following endpoints: a composite endpoint of all-cause mortality, any myocardial infarction (MI), any (unscheduled) revascularization, stroke and TIMI major bleeding, as well as target lesion failure and stent thrombosis (ST).

Results: From a total of 1,100 STEMI patients enrolled in the trial, 998 received a R-ZES. At 6 months the PE occurred in 42 (4.2%) patients. All-cause death, MI, revascularization, stroke and TIMI major bleeding was respectively 8 (0.8%), 9 (0.8%), 34 (3.4%), 2 (0.2%), and 4 (0.4%). The rate of target lesion revascularizations involving the culprit lesion was 1.1%. Target lesion failure was 1.5%. The rate of definite ST was 0.5%. The rate of both definite or probable ST was 0.7%.

Conclusions: The present analysis is the largest to date reporting short-term and mid-term clinical outcomes with the R-ZES stent in setting of STEMI. At 30 days and 6-months R-ZES has an outstanding safety and efficacy even in this high-risk category of patients.

Original languageEnglish
Number of pages6
JournalCatheterization and cardiovascular interventions
DOIs
Publication statusE-pub ahead of print/First online - 3 Jul 2019

Fingerprint

Stents
Thrombosis
Myocardial Infarction
Safety
zotarolimus
ST Elevation Myocardial Infarction
Stroke
Hemorrhage
Myocardial Revascularization
Drug-Eluting Stents
Percutaneous Coronary Intervention
Cause of Death
Mortality

Keywords

  • Acute myocardial infarction
  • Antiplatelet therapy
  • Coronary artery disease
  • Drug-eluting stents (DES)
  • Stent thrombosis

Cite this

Postma, Warner ; Fabris, Enrico ; van der Ent, Martin ; Hermanides, Rik ; Buszman, Pawel ; von Birgelen, Clemens ; Cook, Stéphane ; Wedel, Hans ; De Luca, Giuseppe ; Delewi, Ronak ; Zijlstra, Felix ; Kedhi, Elvin. / Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI) : A prespecified prospective register from the DAPT-STEMI trial. In: Catheterization and cardiovascular interventions. 2019.
@article{a689414cc33b4f63bbe0143c1f4d6102,
title = "Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial",
abstract = "Objectives: To evaluate the safety and efficacy outcomes after primary percutaneous coronary intervention (pPCI) with second-generation Resolute™ zotarolimus-eluting stent (R-ZES) in patients enrolled in the DAPT-STEMI Trial (NCT01459627).Background: R-ZES is one of the most used drug eluting stents worldwide. To date, the safety and efficacy data of this stent in setting of STEMI is limited. Methods: The Resolute-STEMI is a prespecified prospective register that reports the safety and efficacy of R-ZES in setting of ST-Elevation Myocardial Infarction (STEMI) at 6 months for the following endpoints: a composite endpoint of all-cause mortality, any myocardial infarction (MI), any (unscheduled) revascularization, stroke and TIMI major bleeding, as well as target lesion failure and stent thrombosis (ST).Results: From a total of 1,100 STEMI patients enrolled in the trial, 998 received a R-ZES. At 6 months the PE occurred in 42 (4.2{\%}) patients. All-cause death, MI, revascularization, stroke and TIMI major bleeding was respectively 8 (0.8{\%}), 9 (0.8{\%}), 34 (3.4{\%}), 2 (0.2{\%}), and 4 (0.4{\%}). The rate of target lesion revascularizations involving the culprit lesion was 1.1{\%}. Target lesion failure was 1.5{\%}. The rate of definite ST was 0.5{\%}. The rate of both definite or probable ST was 0.7{\%}.Conclusions: The present analysis is the largest to date reporting short-term and mid-term clinical outcomes with the R-ZES stent in setting of STEMI. At 30 days and 6-months R-ZES has an outstanding safety and efficacy even in this high-risk category of patients.",
keywords = "Acute myocardial infarction, Antiplatelet therapy, Coronary artery disease, Drug-eluting stents (DES), Stent thrombosis",
author = "Warner Postma and Enrico Fabris and {van der Ent}, Martin and Rik Hermanides and Pawel Buszman and {von Birgelen}, Clemens and St{\'e}phane Cook and Hans Wedel and {De Luca}, Giuseppe and Ronak Delewi and Felix Zijlstra and Elvin Kedhi",
year = "2019",
month = "7",
day = "3",
doi = "10.1002/ccd.28376",
language = "English",
journal = "Catheterization and cardiovascular interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",

}

Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI) : A prespecified prospective register from the DAPT-STEMI trial. / Postma, Warner; Fabris, Enrico; van der Ent, Martin; Hermanides, Rik; Buszman, Pawel; von Birgelen, Clemens; Cook, Stéphane; Wedel, Hans; De Luca, Giuseppe; Delewi, Ronak; Zijlstra, Felix; Kedhi, Elvin.

In: Catheterization and cardiovascular interventions, 03.07.2019.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI)

T2 - A prespecified prospective register from the DAPT-STEMI trial

AU - Postma, Warner

AU - Fabris, Enrico

AU - van der Ent, Martin

AU - Hermanides, Rik

AU - Buszman, Pawel

AU - von Birgelen, Clemens

AU - Cook, Stéphane

AU - Wedel, Hans

AU - De Luca, Giuseppe

AU - Delewi, Ronak

AU - Zijlstra, Felix

AU - Kedhi, Elvin

PY - 2019/7/3

Y1 - 2019/7/3

N2 - Objectives: To evaluate the safety and efficacy outcomes after primary percutaneous coronary intervention (pPCI) with second-generation Resolute™ zotarolimus-eluting stent (R-ZES) in patients enrolled in the DAPT-STEMI Trial (NCT01459627).Background: R-ZES is one of the most used drug eluting stents worldwide. To date, the safety and efficacy data of this stent in setting of STEMI is limited. Methods: The Resolute-STEMI is a prespecified prospective register that reports the safety and efficacy of R-ZES in setting of ST-Elevation Myocardial Infarction (STEMI) at 6 months for the following endpoints: a composite endpoint of all-cause mortality, any myocardial infarction (MI), any (unscheduled) revascularization, stroke and TIMI major bleeding, as well as target lesion failure and stent thrombosis (ST).Results: From a total of 1,100 STEMI patients enrolled in the trial, 998 received a R-ZES. At 6 months the PE occurred in 42 (4.2%) patients. All-cause death, MI, revascularization, stroke and TIMI major bleeding was respectively 8 (0.8%), 9 (0.8%), 34 (3.4%), 2 (0.2%), and 4 (0.4%). The rate of target lesion revascularizations involving the culprit lesion was 1.1%. Target lesion failure was 1.5%. The rate of definite ST was 0.5%. The rate of both definite or probable ST was 0.7%.Conclusions: The present analysis is the largest to date reporting short-term and mid-term clinical outcomes with the R-ZES stent in setting of STEMI. At 30 days and 6-months R-ZES has an outstanding safety and efficacy even in this high-risk category of patients.

AB - Objectives: To evaluate the safety and efficacy outcomes after primary percutaneous coronary intervention (pPCI) with second-generation Resolute™ zotarolimus-eluting stent (R-ZES) in patients enrolled in the DAPT-STEMI Trial (NCT01459627).Background: R-ZES is one of the most used drug eluting stents worldwide. To date, the safety and efficacy data of this stent in setting of STEMI is limited. Methods: The Resolute-STEMI is a prespecified prospective register that reports the safety and efficacy of R-ZES in setting of ST-Elevation Myocardial Infarction (STEMI) at 6 months for the following endpoints: a composite endpoint of all-cause mortality, any myocardial infarction (MI), any (unscheduled) revascularization, stroke and TIMI major bleeding, as well as target lesion failure and stent thrombosis (ST).Results: From a total of 1,100 STEMI patients enrolled in the trial, 998 received a R-ZES. At 6 months the PE occurred in 42 (4.2%) patients. All-cause death, MI, revascularization, stroke and TIMI major bleeding was respectively 8 (0.8%), 9 (0.8%), 34 (3.4%), 2 (0.2%), and 4 (0.4%). The rate of target lesion revascularizations involving the culprit lesion was 1.1%. Target lesion failure was 1.5%. The rate of definite ST was 0.5%. The rate of both definite or probable ST was 0.7%.Conclusions: The present analysis is the largest to date reporting short-term and mid-term clinical outcomes with the R-ZES stent in setting of STEMI. At 30 days and 6-months R-ZES has an outstanding safety and efficacy even in this high-risk category of patients.

KW - Acute myocardial infarction

KW - Antiplatelet therapy

KW - Coronary artery disease

KW - Drug-eluting stents (DES)

KW - Stent thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85068619480&partnerID=8YFLogxK

U2 - 10.1002/ccd.28376

DO - 10.1002/ccd.28376

M3 - Article

JO - Catheterization and cardiovascular interventions

JF - Catheterization and cardiovascular interventions

SN - 1522-1946

ER -